Clinicians can reassure myelofibrosis patients that the drop in hemoglobin often seen when starting ruxolitinib does not carry the same negative prognostic weight as anemia caused by the disease itself. This distinction is crucial for managing patient expectations and continuing effective therapy despite initial side effects.

While beneficial for patients with prior weight loss, ruxolitinib can cause significant weight gain (20-30 pounds) in other myelofibrosis patients. This quality-of-life issue should be discussed proactively, as it can become a major concern, effectively trading one disease state for another.

Recent Phase 3 trials for novel myelofibrosis combinations (e.g., pelabrasib or selinexor with ruxolitinib) show a consistent pattern. They successfully reduce spleen volume but fail to demonstrate a statistically significant improvement in patient-reported symptom scores compared to ruxolitinib alone, questioning the link between these two endpoints.

The anemia seen in myelofibrosis patients on ruxolitinib is not just a drug side effect but an interaction with the underlying disease. This is proven by the fact that polycythemia vera patients on the same drug do not become anemic, showing the myelofibrotic marrow is uniquely susceptible to the drug's effects.

For patients intolerant to standard TKI starting doses, a "crescendo" approach can be highly effective. This involves starting at a very low dose (e.g., 200mg every other day) and slowly increasing it over several weeks. This gradual escalation allows the body to acclimate, enabling patients to eventually tolerate the full target dose without unacceptable toxicity.

For myelofibrosis patients with both anemia and splenomegaly, a practical approach is to start with ruxolitinib for its superior symptom control. If the subsequent anemia is not well-tolerated, switching to momelotinib allows for a more informed, personalized decision based on the patient's experience with both agents.

Clinicians should interpret anemia in myelofibrosis patients on JAK inhibitors based on its timing. Anemia in the first 16 weeks is an expected on-target effect. In contrast, new anemia in a patient on a stable dose is a warning sign that may indicate disease progression, warranting further investigation.

For older, transplant-ineligible myeloma patients, quadruplet regimens are not administered at full strength. Clinicians proactively reduce doses of bortezomib, lenalidomide, and dexamethasone based on patient fitness and renal function to manage toxicity while maintaining efficacy.

Concerns over arterial events caused physicians to start CML patients on lower, less effective doses of ponatinib. Data shows a start-high (45mg) then reduce strategy is more effective for disease control and safely mitigates side effect risks, contrary to clinical practice.